Company Research Report: KBI Biopharma

Company Overview

• Name: KBI Biopharma

• Mission: KBI Biopharma is dedicated to being a global CDMO (Contract Development and Manufacturing Organization) icon, driving breakthroughs in biopharmaceutical development and manufacturing that positively impact the lives of patients worldwide.

• Foundation: The exact founding date and founders are not specified.

• Key People:

• Tim Lowery, Chief Executive Officer

• Marykay Marchigiani, Chief Financial Officer

• Sigma Mostafa, Chief Scientific Officer

• Peter Carbone, Chief Operating Officer

• Jean-Baptiste Agnus, Chief Business Officer

• Rachel Mandell, Senior VP & General Counsel

• Sarah Wakefield, Senior VP, Global Marketing & Corporate Communications

• Shaguna Seth, Chief of Staff & Global PMO Head

• Katie Edgar, Senior VP, Corporate Strategy & Alliance Management

• Headquarters: Durham, North Carolina

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: KBI Biopharma is recognized for providing innovative biologic solutions as a next-generation CDMO and supporting the development and manufacturing of biopharmaceuticals.

Products

Services Offered

KBI Biopharma offers a wide range of services tailored to the biopharmaceutical industry:

1. Cell Line Development

• Description: Supporting both mammalian-based and microbial-based expression systems.

• Key Features: Efficient development processes using state-of-the-art technologies for stable expression and high-quality protein production.

2. Process Development

• Description: Providing robust, reproducible, and scalable processes for new biologics.

• Key Features: Custom development tailored to client needs, ensuring optimal production.

3. Analytical Development

• Description: Comprehensive services at every phase of the project cycle.

• Key Features: Advanced analytical techniques to resolve complex challenges in biologics.

4. Formulation Development

• Description: Optimizing formulations using a data-driven approach.

• Key Features: Creating stabilized formulations enhancing the drug's efficacy and safety.

5. Characterization

• Description: Enhancing the understanding of molecules through comprehensive services.

• Key Features: Utilizing cutting-edge technologies for thorough characterization.

6. Clinical Manufacturing

• Description: Offering manufacturing services for clinical therapeutics and vaccines.

• Key Features: Reliable practices adhering to regulatory standards.

7. Commercial Manufacturing

• Description: Providing GMP (Good Manufacturing Practice) manufacturing for commercial biotherapeutic supply.

• Key Features: High-standard production ensuring product consistency and quality.

Featured Platforms

1. SUREtechnology Platform™

• Description: Powered by Selexis® for premium, stable, and integrated CHO-based cell line development (CLD).

• Key Features: Versatile, scalable, efficient, and reduces expression bottlenecks swiftly.

2. PUREplatform™

• Description: A new standard of E. Coli expression for clean, efficient therapeutic protein production.

• Key Features: Increased efficiencies, exceptional quality, engineered for commercial use.

Recent Developments

• New Products and Features:

• SUREmAb™ Platform: Launched to offer faster monoclonal antibody development and manufacturing.

• PUREplatform™: Introduced as a microbial expression offering for improved biopharmaceutical manufacturing.

• Strategic Alliances:

• Collaboration with Argonaut Manufacturing Services to provide end-to-end biopharmaceutical development and cGMP solutions.

• Leadership Appointments:

• Jean-Baptiste Agnus was appointed Chief Business Officer.

• Chief Quality Officer appointed to strengthen regulatory affairs expertise.

• Recognition:

• Received multiple awards in the 2024 CDMO Leadership Awards, highlighting their industry-leading status.

• Conference Participation:

• Active participation in events such as PharmaLab 2024, Korea Life Science Week, and BIO-Europe to showcase their latest innovations and connect with industry stakeholders.

• Operational Developments:

• Ongoing operational consolidation with Selexis to improve service delivery and accelerate project timelines.

This research report, compiled using the available data, outlines KBI Biopharma's prominent role as a leader in biopharmaceutical development and manufacturing, emphasizing its commitment to innovation and client-focused service approach.